454’s GS20 Can Detect Mutations In Tumors Sanger Missed; Research Could Buoy Solexa, Helicos, Agencourt | GenomeWeb
NEW YORK (GenomeWeb News) - At least two teams of scientists have been exploring the ability of 454 Life Sciences’ platform to detect mutations in tumors, testing the potential advantages of massively parallel sequencing over traditional DNA sequencing for this application.
In the short term, these studies might help decide whether the Genome Sequencer 20 platform will become part of the NIH’s Cancer Genome Atlas pilot project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.